Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.

While maintaining a standard toceranib dosage [2.75 mg kg(-1) , PO, every other day (EOD)], three dose-escalating CCNU cohorts up to and including 60 mg m(-2) , PO, q3wk, were completed. The dose-limiting toxicities (DLT) for the combination were neutropenia and the maximum tolerated dose (MTD) for CCNU when given with continuous toceranib was determined to be 50 mg m(-2) , q3wk. While activity is not a primary objective of phase I trials, we observed one complete (lymphoma) and four partial responses (lymphoma, sarcoma, undifferentiated carcinoma and prostatic carcinoma) and two dogs experienced stable disease for >6 weeks [gastric adenocarcinoma and metastatic multilobulated osteochondrosarcoma (MLO)] for an objective response rate of 38.4% and a biological response rate of 53.8%. Concurrent continuous toceranib (2.75 mg kg(-1) , EOD) and pulse dose CCNU (50 mg m(-2) , q3wk) was well tolerated. Phase II effectiveness and phase III prospective randomized trials should further interrogate the potential activity of this combination.

[1]  M. Pennell,et al.  Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose , 2013, BMC Veterinary Research.

[2]  D. Thamm,et al.  Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. , 2012, Veterinary and comparative oncology.

[3]  D. Vail,et al.  Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. , 2012, Veterinary and comparative oncology.

[4]  C. London,et al.  Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study. , 2012, Veterinary and comparative oncology.

[5]  C. Rodriguez,et al.  Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. , 2011, Journal of veterinary internal medicine.

[6]  N. Northrup,et al.  Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. , 2010, Journal of veterinary internal medicine.

[7]  D. Russell,et al.  A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. , 2010, Veterinary and comparative oncology.

[8]  J. Boucher,et al.  Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. , 2010, Journal of veterinary pharmacology and therapeutics.

[9]  S. Marsh,et al.  Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. , 2010, Journal of veterinary pharmacology and therapeutics.

[10]  C. Khanna,et al.  Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2010, Veterinary and comparative oncology.

[11]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[12]  F. Millanta,et al.  Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. , 2010, Journal of comparative pathology.

[13]  D. Haines,et al.  Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas. , 2009, Journal of comparative pathology.

[14]  D. Malarkey,et al.  Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. , 2009, Veterinary and comparative oncology.

[15]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[16]  D. Haines,et al.  Immunohistochemical Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Associated with Tumor Cell Proliferation in Canine Cutaneous Squamous Cell Carcinomas and Trichoepitheliomas , 2007, Veterinary pathology.

[17]  D. Vail Cancer clinical trials: development and implementation. , 2007, The Veterinary clinics of North America. Small animal practice.

[18]  G. Scagliotti Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  W. Pickl,et al.  Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. , 2007, Veterinary immunology and immunopathology.

[20]  D. Thamm,et al.  Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. , 2007, Journal of veterinary internal medicine.

[21]  F. Millanta,et al.  The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. , 2006, Research in veterinary science.

[22]  P. Bergman,et al.  Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). , 2006, Journal of veterinary internal medicine.

[23]  H. Sakai,et al.  Expression of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Their Receptors (Flt-1, Flk-1, and Flg-1) in Canine Vascular Tumors , 2006, Veterinary pathology.

[24]  J. Pujol,et al.  Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  S. Platt,et al.  Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. , 2006, Journal of veterinary internal medicine.

[26]  J. Sur,et al.  Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer. , 2006, The Journal of veterinary medical science.

[27]  S. Lana,et al.  CCNU in the treatment of canine epitheliotropic lymphoma. , 2006, Journal of veterinary internal medicine.

[28]  N. Shenoy,et al.  Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  N. Shenoy,et al.  Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. , 2002, Blood.

[30]  G. De Vico,et al.  Expression of Vascular Endothelial Growth Factor in Canine Mammary Tumors , 2002, Veterinary pathology.

[31]  G. De Vico,et al.  Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. , 2000, Journal of comparative pathology.

[32]  D. Waxman,et al.  1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels. , 1994, Drug metabolism and disposition: the biological fate of chemicals.